Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia
Metrics: PDF 1111 views | HTML 1348 views | ?
Lin Fu1,*, Jinlong Shi2,*, Kai Hu1, Jijun Wang1, Weidong Wang2 and Xiaoyan Ke1
1 Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing, China
2 Medical Engineering Support Center, Chinese PLA General Hospital, Beijing, China
* These authors contributed equally to this work
Xiaoyan Ke, email:
Weidong Wang, email:
Keywords: MAPKBP1, prognostic biomarker, CN-AML
Received: January 08, 2015 Accepted: February 03, 2015 Published: March 10, 2015
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is a key transcription factor in the NF-κB signalling pathway. In this study, associations between MAPKBP1 expression and molecular and clinical characteristics were evaluated by several microarray datasets. We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow. High MAPKBP1 expression (MAPKBP1high) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1low) in a cohort of 157 CN-AML patients. In multivariable analyses, MAPKBP1high remained associated with shorter EFS (P = 0.003) and OS (P = 0.01). Validation in an independent cohort of 162 CN-AML patients further confirmed the prognostic value of MAPKBP1 (OS, P = 0.00172). Gene-expression profiling revealed that some important oncogenes, including MYCN, MYB, CDK6 and CCND2, etc, were up-regulated, while cell signalling pathways leading to apoptosis, antigen processing, and natural killer cell-mediated cytotoxicity were down-regulated in MAPKBP1high patients with CN-AML. MicroRNA expression profiling revealed thatsome oncogenic microRNAsincluding miR-155 and miR-126 were up-regulated, whilst anti-oncogenic microRNAsincluding miR-148a and miR-193a were down-regulated in MAPKBP1high patients with CN-AML, which may underlie the pathological processes in this malignancy. Taken together, these findings suggest MAPKBP1highis a novel, unfavourably prognostic biomarker for CN-AML risk-stratification.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.